Skip to main content

Crescent Capital BDC, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

CCAP$9.38-0.7%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Notes to Consolidated Financial Statements (Unaudited)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

March 31, 2025 (Unaudited)

Note 1. Organization and Basis of Presentation

Crescent Capital BDC, Inc. (the “Company”) was formed on February 5, 2015 as a Delaware corporation structured as an externally managed, closed-end management investment company. The Company commenced investment operations on June 26, 2015. On January 30, 2020, the Company changed its state of incorporation from the State of Delaware to the State of Maryland. The Company was listed and began trading on the NASDAQ stock exchange on February 3, 2020. The Company has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940 (the “1940 Act”) and currently operates as a diversified investment company. In addition, the Company has elected to be treated for U.S. federal income tax purposes as a regulated investment company (a “RIC”) under Subchapter M of the Internal Revenue Code of 1986 (the “Code”). As a RIC, the Company is not taxed on its income to the extent that it distributes such income each year and satisfies other applicable income tax requirements.

The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. The Company invests primarily in secured debt (including first lien, unitranche first lien and second lien debt) and unsecured debt (including mezzanine and subordinated debt), as well as related equity securities of private U.S. middle-market companies. Although the Company’s focus is to invest in private credit transactions, in certain circumstances it may also invest in broadly syndicated loans and bonds.

The Company is managed by Crescent Cap Advisors, LLC (the “Adviser”), an investment adviser that is registered with the Securities and Exchange Commission (the “SEC”) under the Investment Advisers Act of 1940. CCAP Administration LLC (the “Administrator”) provides the administrative services necessary for the Company to operate. Company management consists of investment and administrative professionals from the Adviser and Administrator, along with the Company’s Board of Directors (the “Board”). The Adviser directs and executes the investment operations and capital raising activities of the Company subject to oversight from the Board, which sets the broad policies of the Company. The Board has delegated investment management of the Company’s portfolio assets to the Adviser. The Board consists of six directors, five of whom are independent.

From time to time, the Company may form wholly owned subsidiaries to facilitate the normal course of business if the Adviser determines that for legal, tax, regulatory, accounting or other similar reasons it is in the best interest of the Company to do so. The Company has formed or acquired wholly owned subsidiaries that are structured as tax blockers, to hold equity or equity-like investments in portfolio companies organized as limited liability companies or other forms of pass-through entities. These corporate subsidiaries are not consolidated for income tax purposes and may incur income tax expenses as a result of its ownership of portfolio companies. The Company has also formed a special purpose vehicle that holds certain debt investments in connection with a credit facility.

Basis of Presentation

The Company’s functional currency is the United States dollar and these consolidated financial statements have been prepared in that currency. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to Regulation S-X. The Company is an investment company and, therefore, applies the specialized accounting and reporting guidance in Accounting Standards Codification (“ASC”) 946, Financial Services – Investment Companies.

The accompanying consolidated financial statements of the Company and related financial information have been prepared pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications consisting solely of normal accruals that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the year ending December 31, 2025.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

Thepreparation of the consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that may affect the amounts reported in the consolidated financial statements and accompanying notes. These consolidated financial statements reflect adjustments that in the opinion of management are necessary for the fair statement of theresults for the periods presented. Although management believes that the estimates and assumptions are reasonable, changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits and may include highly liquid investments (e.g., money market funds, U.S. Treasury notes, and similar type instruments) with original maturities of three months or less. Cash and cash equivalents other than money market mutual funds, are carried at cost plus accrued interest, which approximates fair value. Money market mutual funds are carried at their net asset value, which approximates fair value. Cash equivalents held by the Company are deemed to be a Level 1 asset per ASC 820 Fair Value hierarchy, as defined below. Restricted cash and cash equivalents consists of deposits and cash collateral held at Wells Fargo Bank N.A. related to the Company’s credit facility. The Company holds cash and cash equivalents denominated in foreign currencies. The Company deposits its cash, cash equivalents and restricted cash with highly rated banking corporations and, at times, cash deposits may exceed the insured limits under applicable law.

Investment Transactions

Loan originations are recorded on the date of the binding commitment. Investments purchased on a secondary market are recorded on the trade date. Realized gains or losses are recorded using the specific identification method as the difference between the net proceeds received (excluding prepayment fees, if any) and the amortized cost basis of the investment without regard to unrealized gains or losses previously recognized, and include investments written off during the period, net of recoveries. The net change in unrealized gains or losses primarily reflects the change in investment fair values as of the last day of the reporting period and also includes the reversal of previously recorded unrealized gains or losses with respect to investments realized during the period.

Investment Valuation

The Company applies Financial Accounting Standards Board ASC 820, Fair Value Measurement (ASC 820), which establishes a framework for measuring fair value in accordance with GAAP and required disclosures of fair value measurements. ASC 820 determines fair value to be the price that would be received for an investment in a current sale, which assumes an orderly transaction between market participants on the measurement date. Market participants are defined as buyers and sellers in the principal or most advantageous market (which may be a hypothetical market) that are independent, knowledgeable, and willing and able to transact. In accordance with ASC 820, the Company considers its principal market to be the market that has the greatest volume and level of activity. ASC 820 specifies a fair value hierarchy that prioritizes and ranks the level of observability of inputs used in the determination of fair value. In accordance with ASC 820, these levels are summarized below:

Level 1—Valuations based on quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2—Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Investments for which market quotations are readily available are typically valued at those market quotations. To validate market quotations, the Adviser utilizes a number of factors to determine if the quotations are representative of fair value, including the source and number of the quotations. With respect to investments for which market quotations are not readily available, or for which market quotations are deemed not reflective of the fair value, the Adviser, as the Board’s valuation designee, determines the fair value of the investments in good faith, based on, among other things, the fair valuation recommendations from investment professionals, the input of the Company’s Audit Committee and independent third-party valuation firms.

The SEC has adopted Rule 2a-5 (the “Rule”) under the 1940 Act. The Rule establishes requirements for determining fair value in good faith for purposes of the 1940 Act. Pursuant to the Rule, the Board has designated the Adviser as valuation designee (the “Valuation Designee”) to perform certain fair value functions, including performing fair value determinations. As required by the Rule, the Valuation Designee provides periodic fair valuation reporting and notifications on behalf of the Company to the Board to facilitate the Board’s oversight duties.

The Adviser, as the Valuation Designee, undertakes a multi-step valuation process under the supervision of the Board, which includes, among other procedures, the following:

Each investment is initially valued by the investment professionals responsible for monitoring that investment.

The Adviser has established pricing and valuation committees, which are responsible for reviewing and approving the fair valuation recommendations from the investment professionals.

The valuations of certain portfolio investments are independently corroborated by third-party valuation firms based on certain criteria including investment size and risk profile.

Final valuation determinations and supporting materials are provided to the Board quarterly as part of the Board's oversight of the Adviser as the valuation designee.

Investments in investment companies are valued at fair value. Fair values are generally determined utilizing the net asset value (“NAV”) supplied by, or on behalf of, management of each investment company, which is net of management and incentive fees or allocations charged by the investment company and is in accordance with the “practical expedient”, as defined by ASC 820. NAVs received by, or on behalf of, management of each investment company are based on the fair value of the investment company’s underlying investments in accordance with policies established by management of each investment company, as described in each of their financial statements and offering memorandum. Investments which are valued using NAV as a practical expedient are excluded from the above hierarchy.

The Company applies the valuation policy approved by the Board that is consistent with ASC 820. Consistent with the valuation policy, the Adviser, in its capacity as the Valuation Designee, evaluates the source of inputs, including any markets in which its investments are trading (or any markets in which securities with similar attributes are trading), in determining fair value. When a security is valued based on prices provided by reputable dealers or pricing services (that is, broker quotes), the Company subjects those prices to various criteria in making the determination as to whether a particular investment would qualify for classification as a Level 2 or Level 3 investment. For example, the Company reviews pricing methodologies provided by dealers or pricing services in order to determine if observable market information is being used, versus unobservable inputs. Some additional factors considered include the number of prices obtained as well as an assessment as to their quality. Transfers between levels, if any, are recognized at the beginning of the period in which the transfers occur.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of such investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that may ultimately be realized. Further, such investments are generally less liquid than publicly traded securities and may be subject to contractual and other restrictions on resale. If the Company were required to liquidate a portfolio investment in a forced or liquidation sale, it could realize amounts that are different from the amounts presented and such differences could be material. In addition, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the unrealized gains or losses reflected herein.

Foreign Currency

Foreign currency amounts are translated into U.S. dollars on the following basis:

cash and cash equivalents, fair value of investments, outstanding debt on revolving credit facilities, other assets and liabilities: at the spot exchange rate on the last business day of the period; and

purchases and sales of investments, borrowings and repayments of such borrowings, income and expenses: at the rates of exchange prevailing on the respective dates of such transactions.

Although net assets and fair values are presented based on the applicable foreign exchange rates described above, the Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in fair values of investments held. Gains or losses on foreign currency transactions are included with net realized gain (loss) on foreign currency transactions on the Consolidated Statements of Operations. Fluctuations arising from the translation of foreign currency on cash, investments and borrowings are included with net change in unrealized appreciation (depreciation) on investments and foreign currency translation on the Consolidated Statements of Operations.

The Company’s approach to hedging the foreign currency exposure in its non-U.S. dollar denominated investments is to borrow local currency under the Company’s credit facilities or to enter into foreign currency forward contracts.

Foreign Currency Forward Contracts

The Company may enter into foreign currency forward contracts to reduce the Company’s exposure to foreign currency exchange rate fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another, at a pre-determined price at a future date. Forward foreign currency contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts are recorded on the Consolidated Statements of Assets and Liabilities on a gross basis, not taking into account collateral posted which is recorded separately, if applicable. All foreign currency forward contracts are currently held with a single counterparty. Notional amounts and the gross fair value of foreign currency forward contract assets and liabilities are presented separately on the Consolidated Schedules of Investments. Purchases and sales of foreign currency forward contracts having the same notional value, settlement date and counterparty are generally settled net (which results in a net foreign currency position of zero with the counterparty) and any realized gains or losses are recognized on the settlement date.

The Company does not utilize hedge accounting and as such, the Company recognizes its derivatives at fair value with changes in the net unrealized appreciation (depreciation) on foreign currency forward contracts recorded on the Consolidated Statements of Operations.

Debt Issuance Costs

The Company records costs related to the issuance of debt obligations as deferred financing costs. These costs are amortized over the life of the related debt instrument using the straight-line method. See Note 6 for details.

Equity Offering Expenses

Deferred offering costs consist of fees paid in relation to legal, accounting, regulatory and printing work completed in preparation of equity offerings and are included in other assets on the Consolidated Statements of Assets and Liabilities. These costs are charged as a reduction of paid-in-capital upon the closing of the related offering.

Interest and Dividend Income Recognition

Interest income is recorded on an accrual basis and includes the amortization of purchase discounts and premiums. Discounts and premiums to par value are accreted or amortized into interest income over the contractual life of the respective security using the effective yield method. The amortized cost of investments represents the original cost adjusted for the accretion and amortization of discounts and premiums, if any. Upon prepayment of a loan or debt security, any prepayment premiums, unamortized upfront loan origination fees and unamortized discounts are recorded as interest income.

Dividend income from common equity securities is recorded on the record date for private portfolio companies or on the ex-dividend date for publicly-traded portfolio companies. Dividend income from preferred equity securities is recorded on an accrual basis to the extent that such amounts are payable by the portfolio company and are expected to be collected. Each distribution received from an equity investment is evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from equity investments as dividend income unless there is sufficient current or accumulated earnings prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.

Certain investments have contractual payment-in-kind (“PIK”) interest or dividends. PIK represents accrued interest or accumulated dividends that are added to the loan principal or cost basis of the investment on the respective interest or dividend payment dates rather than being paid in cash and generally becomes due at maturity or upon being called by the issuer. PIK is recorded as interest income, as applicable. If at any point the Company believes PIK is not expected to be realized, the investment generating PIK will be placed on non-accrual status. Accrued PIK interest or dividends are generally reversed through interest or dividend income, respectively, when an investment is placed on non-accrual status.

Loans are generally placed on non-accrual status when principal or interest payments are past due 30 days or more or when there is reasonable doubt that principal or interest will be collected in full. Accrued and unpaid interest is generally reversed when a loan is placed on non-accrual status. Interest payments received on non-accrual loans may be recognized as income or applied to principal depending upon management’s judgment regarding collectability. Non-accrual loans are restored to accrual status when past due principal and interest is paid current and, in management’s judgment, are likely to remain current. Management may determine to not place a loan on non-accrual status if the loan has sufficient collateral value and is in the process of collection. As of March 31, 2025, we hadtwenty two investments across nine portfolio companies on non-accrual status, which represented 3.5% and 1.8% of the total debt investments at cost and fair value, respectively. As of December 31, 2024, we hadeighteen investments across seven portfolio companies on non-accrual status, which represented 2.2% and 0.9% of the total debt investments at cost and fair value, respectively. The remaining debt investments were performing and current on their interest payments as of March 31, 2025 and December 31, 2024.

Other Income

Other income may include income such as consent, waiver, amendment, agency, underwriting and arranger fees associated with the Company’s investment activities. Such fees are recognized as income when earned or the services are rendered.

Income Taxes

The Company has elected to be treated as a BDC under the 1940 Act. The Company also has elected to be treated as a RIC under the Internal Revenue Code. So long as the Company maintains its status as a RIC, it will generally not pay corporate-level U.S. federal income or excise taxes on any ordinary income or capital gains that it distributes at least annually to its stockholders as dividends. As a result, any tax liability related to income earned and distributed by the Company represents obligations of the Company’s stockholders and will not be reflected in the consolidated financial statements of the Company.

The Company evaluates tax positions taken or expected to be taken in the course of preparing its consolidated financial statements to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are reversed and recorded as a tax benefit or expense in the current year. All penalties and interest associated with income taxes are included in income tax expense. Conclusions regarding tax positions are subject to review and may be adjusted at a later date based on factors including, but not limited to, on-going analyses of tax laws, regulations and interpretations thereof. The Company accounts for income taxes in conformity with ASC 740 — Income Taxes (“ASC 740”). ASC 740 provides guidelines for how uncertain tax positions should be recognized, measured, presented and disclosed in financial statements.

The Company intends to comply with the applicable provisions of the Code, pertaining to regulated investment companies and to make distributions of taxable income sufficient to relieve it from substantially all federal income taxes. As of March 31, 2025 the Company is subject to potential examination by U.S. federal tax authorities for returns filed for the three most recent calendar years and by state tax authorities for returns filed for the four most recent calendar years.

In order for the Company not to be subject to federal excise taxes, it must distribute annually an amount at least equal to the sum of (i) 98% of its ordinary income (taking into account certain deferrals and elections), (ii) 98.2% of its net capital gains from the current year and (iii) any undistributed ordinary income and net capital gains from preceding years. The Company, at its discretion, may carry forward taxable income in excess of calendar year dividends and pay a 4% excise tax on this income. If the Company chooses to do so, this generally would increase expenses and reduce the amount available to be distributed to stockholders. The Company accrues excise tax on estimated undistributed taxable income as required on a quarterly basis.

CBDC Universal Equity, Inc. and First Eagle OEMG Investor, Inc., are wholly-owned subsidiaries of the Company, and taxable entities (“Taxable Subsidiaries”). The Taxable Subsidiaries permit the Company to hold equity investments in portfolio companies which are “pass through” entities for tax purposes and continues to comply with the “source income” requirements contained in RIC tax provisions of the Code. The Taxable Subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, benefit, and the related tax assets and liabilities, as a result of its ownership of certain portfolio investments. The income tax expense, or benefit, if any, and related tax assets and liabilities are reflected in the Company’s consolidated financial statements. See Note 11 for details.

Dividends and Distributions to Stockholders

Dividends and distributions to common stockholders are recorded on the record date. The amount to be paid out as a dividend is determined by the Board each quarter. Net realized capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.

The Company adopted a dividend reinvestment plan that provides for reinvestment of the Company’s dividends and other distributions on behalf of the stockholders unless a stockholder elects to receive cash. As a result, if the Company’s Board authorizes, and the Company declares, a cash dividend, or other distribution then stockholders who are participating in the dividend reinvestment plan will have their cash dividends and distributions automatically reinvested in additional shares of common stock, rather than receiving cash dividends and distributions.

Segment Reporting

Since its commencement, the Company has operated and been managed as asingle reportable segment deriving returns mainly in the form of interest income, dividend income and other fees from the investments made in pursuit of its single stated investment objective. The accounting policies of the Company are consistent with those described in these Notes to Consolidated Financial Statements. The chief operating decision maker (“CODM”) is represented by an executive committee comprised of achief executive officer, a chief financial officer and other executive officers of the Company. The CODM considers net investment income, leverage and net increase (decrease) in net assets resulting from operations in deciding how to deploy capital and/or make distributions to shareholders. Detailed financial information for the Company is disclosed within these financial statements with total assets and liabilities disclosed on the Consolidated Statements of Assets and Liabilities, investments held on the Consolidated Schedules of Investments, results of operations and significant segment expenses on the Consolidated Statements of Operations and other information about the Company's performance, including total return, portfolio turnover and ratios within the Financial Highlights in Note 12.

Note 3. Agreements and Related Party Transactions

Administration Agreement

On June 2, 2015, the Company entered into the administration agreement with the Administrator, as amended and restated on February 1, 2020 (the “Administration Agreement”). Under the terms of the Administration Agreement, the Administrator provides administrative services to the Company. These services include providing office space, equipment and office services, maintaining financial records, preparing reports to stockholders and reports filed with the SEC, and managing the payment of expenses and the performance of administrative and professional services rendered by others. Certain of these services are reimbursable to the Administrator under the terms of the Administration Agreement. In addition, the Administrator is permitted to delegate its duties under the Administration Agreement to affiliates or third parties. To the extent the Administrator outsources any of its functions, the Company will pay the fees associated with such functions on a direct basis, without incremental profit to the Administrator. The Administration Agreement may be terminated by either party without penalty on 60 days’ written notice to the other party.

For the three months ended March 31, 2025 and 2024, the Company incurred administrative services expenses of$445 and $343, respectively, which are included in other general and administrative expenses on the Consolidated Statements of Operations. As of March 31, 2025 and December 31, 2024,$725 and $555, respectively, was payable to the Administrator which is included in the accrued expenses and other liabilities on the Consolidated Statements of Assets and Liabilities. In addition to administrative services expenses, the payable balances may include other operating expenses paid by the Administrator on behalf of the Company.

No person who is an officer, director or employee of the Administrator or its affiliates and who serves as a director of the Company receives any compensation from the Company for his or her services as a director. However, the Company reimburses the Administrator (or its affiliates) for an allocable portion of the compensation paid by the Administrator or its affiliates to the Company’s accounting professionals, legal counsel, and compliance professionals who spend time on such related activities (based on the percentage of time those individuals devote, on an estimated basis, to the business and affairs of the Company). The allocable portion of the compensation for these officers and other professionals is included in the administration expenses paid to the Administrator. Directors who are not affiliated with the Administrator or its affiliates receive compensation for their services and reimbursement of expenses incurred to attend meetings, which are included as directors’ fees on the Consolidated Statements of Operations.

Investment Advisory Agreement

On June 2, 2015, the Company entered into an investment advisory agreement with the Adviser which was most recently amended and restated on January 5, 2021 (the “Investment Advisory Agreement”). Under the terms of the Investment Advisory Agreement, the Adviser provides investment advisory services to the Company and its portfolio investments. The Adviser’s services under the Investment Advisory Agreement are not exclusive, and the Adviser is free to furnish similar or other services to others so long as its services to the Company are not impaired. Under the terms of the Investment Advisory Agreement, the Adviser is entitled to receive a base management fee and may also receive incentive fees, as discussed below.

Base Management Fee

The base management fee is calculated and payable quarterly in arrears at an annual rate of 1.25% of the Company’s gross assets, including assets acquired through the incurrence of debt but excluding any cash, cash equivalents and restricted cash. The base management fee is calculated based on the average value of gross assets at the end of the two most recently completed calendar quarters, and appropriately adjusted for any share issuances or repurchases during the current calendar quarter. For purposes of the Investment Advisory Agreement, cash equivalents means U.S. government securities and commercial paper maturing within one year of purchase. Under the terms of the Investment Advisory Agreement, the Adviser has voluntarily waived its right to receive management fees on the Company’s investments in GACP II LP, WhiteHawk III Onshore Fund LP and Freeport Financial SBIC Fund LP for any period in which these investments remain in the investment portfolio.

For the three months ended March 31, 2025 and 2024, the Company incurred management fees of$5,038 and $4,980, respectively, of which$20 and $38, respectively, were waived. As of March 31, 2025 and December 31, 2024, management fees of$5,019 and $5,066, respectively, were unpaid.

Incentive Fee per Investment Advisory Agreement

Under the Investment Advisory Agreement, the incentive fee consists of two parts:

The first part, the income incentive fee, is calculated and payable quarterly in arrears and (a) equals 100% of the excess of the pre-incentive fee net investment income for the immediately preceding calendar quarter, over a preferred return of 1.75% per quarter (7.0% annualized) (the “Hurdle”), and a catch-up feature until the Adviser has received 17.5% of the pre-incentive fee net investment income for the current quarter up to 2.1212% (the “Catch-up”), and (b)17.5% of all remaining pre-incentive fee net investment income above the “Catch-up.”

The second part, the capital gains incentive fee, is determined and payable in arrears as of the end of each fiscal year at a rate of 17.5% of the Company’s realized capital gains, if any, on a cumulative basis from the Company’s inception through the end of the fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees. In the event that the Investment Advisory Agreement shall terminate as of a date that is not a fiscal year end, the termination date shall be treated as though it were a fiscal year end for purposes of calculating and paying a capital gains incentive fee.

The Adviser voluntarily waived its right to receive the income incentive fees attributable to the investment income accrued by the Company as a result of its investments in GACP II LP, WhiteHawk III Onshore Fund LP and Freeport Financial SBIC Fund LP.

Pre-incentive fee net investment income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued during each calendar quarter, minus operating expenses for such quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and distributions paid on any issued and outstanding debt or preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as market discount, original issue discount, debt instruments with PIK interest, preferred stock with PIK dividends and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Pre-incentive fee net investment income will be compared to a “Hurdle Amount” equal to the product of (i) the Hurdle rate of 1.75% per quarter, or 7.0% annualized, and (ii) our net assets (defined as total assets less indebtedness, before taking into account any incentive fees payable during the period), at the end of the immediately preceding calendar quarter, subject to a “catch-up” provision incurred at the end of each calendar quarter.

For the three months ended March 31, 2025 and 2024, the Company incurred income incentive fees of $3,519 and $4,937, respectively, of which $32 and $36, respectively, were waived. As of March 31, 2025 and December 31, 2024, income incentive fees of$3,487 and $4,305, respectively, were unpaid.

GAAP Incentive Fee on Cumulative Unrealized Capital Appreciation

The Company accrues, but does not pay, a portion of the incentive fee based on capital gains with respect to net unrealized appreciation. Under GAAP, the Company is required to accrue an incentive fee based on capital gains that includes net realized capital gains and losses and net unrealized capital appreciation and depreciation on investments held at the end of each period. In calculating the accrual for the incentive fee based on capital gains, the Company considers the cumulative aggregate unrealized capital appreciation in the calculation, since an incentive fee based on capital gains would be payable if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee payable under the Investment Advisory Agreement. This accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital appreciation or depreciation. If such amount is positive at the end of a period, then the Company records a capital gains incentive fee equal to 17.5% of such amount, minus the aggregate amount of actual incentive fees based on capital gains paid in all prior periods. If such amount is negative, then there is no accrual for such period. There can be no assurance that such unrealized capital appreciation will be realized in the future.

For the three months ended March 31, 2025 and 2024, the Company recordedno capital gains incentive fees on unrealized capital appreciation. As of March 31, 2025 and December 31, 2024, no capital gains incentive fees remain outstanding.

Other Related Party Transactions

From time to time, the Administrator may pay amounts owed by the Company to third-party providers of goods or services, including the Board, and the Company will subsequently reimburse the Administrator for such amounts paid on its behalf. Amounts payable to the Administrator are settled in the normal course of business without formal payment terms.

A portion of the outstanding shares of the Company’s common stock is owned by Crescent Capital Group LP ("Crescent"), its employees and certain officers and directors of the Company. As of March 31, 2025 and December 31, 2024, Crescent, its employees and certain officers and directors of the Company owned 2.75% and 2.74%, respectively, of the Company’s outstanding common stock. Crescent is also the majority member of the Adviser and sole member of the Administrator. The Company has entered into a license agreement with Crescent under which Crescent granted the Company a non-exclusive, royalty-free license to use the name “Crescent Capital”. The Adviser has entered into a resource sharing agreement with Crescent. Crescent will provide the Adviser with the resources necessary for the Adviser to fulfill its obligations under the Investment Advisory Agreement.

As of each of March 31, 2025 and December 31, 2024, Sun Life Financial Inc. ("Sun Life"), a majority owner of Crescent, owned 6.01%, of the Company’s outstanding common stock. Sun Life is the sole lender of the Company’s Series 2023A Unsecured Notes, a $10,000 participating lender in the Company’s Series 2021A Unsecured Notes, a $2,000 participating lender the Company's Series 2024 Unsecured Notes - 2028, and a $10,000 participating lender the Company's Series 2024 Unsecured Notes - 2030, all described further in Note 6.

Investments in affiliated and controlled companies

Under the 1940 Act, the Company is required to separately identify non-controlled investments where it owns, either directly or indirectly,5% or more of a portfolio company’s outstanding voting securities and/or has the power to exercise control over the management or policies of such portfolio company as investments in “affiliated” companies. In addition, under the 1940 Act, the Company is required to separately identify investments where it owns, either directly or indirectly, more than 25%of a portfolio company’soutstanding voting securities and/or has the power to exercise control over the management or policies of such portfolio company as investments in “controlled” companies. Detailed information with respect to the Company’s non-controlled, non-affiliated; non-controlled, affiliated; and controlled affiliated investments is contained in the accompanying consolidated financial statements, including the Consolidated Schedule of Investments and the summary tables below.

The Company’s investments in non-controlled affiliates for the three months ended March 31, 2025 were as follows (in thousands):

Fair Value as of December 31, 2024Gross Additions (1)Gross Reductions (2)Net Realized Gains/(Losses)Change in Unrealized Gains/(Losses)Fair Value as of March 31, 2025Dividend, Interest, PIK and Other Income
Non-Controlled Affiliates
AX VI INV2 Holding AB$15,110$261$—$—$965$16,336$353
ASP MCS Acquisition728———25753—
Bayside Opco, LLC7,92098(14)—7748,778276
Isagenix International, LLC2,00583——(390)1,698101
Slickdeals Holdings, LLC14,76619(38)—(725)14,022392
Vivid Seats Ltd.910———(182)728—
WhiteHawk III Onshore Fund L.P.5,354—(1,730)—(134)3,490258
Total Non-Controlled Affiliates$46,793$461$(1,782)$—$333$45,805$1,380

The Company’s investments in non-controlled affiliates for the three months ended March 31, 2024 were as follows (in thousands):

Fair Value as of December 31, 2023Gross Additions (1)Gross Reductions (2)Net Realized Gains/(Losses)Change in Unrealized Gains/(Losses)Fair Value as of March 31, 2024Dividend, Interest, PIK and Other Income
Non-Controlled Affiliates
AX VI INV2 Holding AB$14,152$248$—$—$(43)$14,357$339
ASP MCS Acquisition799346(1)—141,15810
Bayside Opco, LLC6,704189——2527,145190
GACP II, LP3,927—(2,855)—711,143—
Isagenix International, LLC2,54672——(32)2,58691
Slickdeals Holdings, LLC15,19226(37)—(72)15,109444
smarTours, LLC—23——(23)——
Vivid Seats Ltd.1,021———201,041—
WhiteHawk III Onshore Fund L.P.8,278—(240)—418,079287
Total Non-Controlled Affiliates$52,619$904$(3,133)$—$228$50,618$1,361

(1)

Gross additions may include increases in the cost basis of investments resulting from new portfolio investments, PIK interest or dividends, the accretion of discounts, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company into this category from a different category.

(2)

Gross reductions may include decreases in the cost basis of investments resulting from principal collections related to investment repayments or sales, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company out of this category into a different category.

The Company’s investments in controlled affiliates for the three months ended March 31, 2025 were as follows (in thousands):

Fair Value as of December 31, 2024Gross Additions (2)Gross Reductions (3)Net Realized Gains/(Losses)Change in Unrealized Gains/(Losses)Fair Value as of March 31, 2025Dividend, Interest, PIK and Other Income
Controlled Affiliates
Envocore LLC$9,221$1,112$(17)$—$(53)$10,264$170
First Eagle Logan JV, LLC(1)32,575—(1)—1,47734,0511,200
Loadmaster Derrick & Equipment, Inc.3,476———(190)3,28538
OEM Group, LLC2,779—(2,214)(3,800)3,235——
Total Controlled Affiliates$48,051$1,112$(2,232)$(3,800)$4,469$47,600$1,408

The Company’s investments in controlled affiliates for the three months ended March 31, 2024 were as follows (in thousands)

Fair Value as of December 31, 2023Gross Additions (2)Gross Reductions (3)Net Realized Gains/(Losses)Change in Unrealized Gains/(Losses)Fair Value as of March 31, 2024Dividend, Interest, PIK and Other Income
Controlled Affiliates
Envocore LLC$10,375$1,615$(695)$—$(2,074)$9,221$614
First Eagle Logan JV, LLC(1)39,004—(2,559)—(3,870)32,5759,784
Loadmaster Derrick & Equipment, Inc.6,287—(3,750)6,443(5,504)3,476471
OEM Group, LLC8,253(322)(1,669)—(3,483)2,779—
Total Controlled Affiliates$63,919$1,293$(8,673)$6,443$(14,931)$48,051$10,869

(1)

Together with Perspecta Trident LLC (“Perspecta”), the Company invests through First Eagle Logan JV, LLC, which holds 100% of the subordinated notes and 100% of the Class E Notes issued by LJV I MM CLO LLC, its consolidated subsidiary (together, "Logan JV"). Logan JV is not an extension of the Company’s investment operations given shared power/voting rights with Perspecta. The Company owns 80% of the voting securities of the Logan JV, but the Company does not have control over the Logan JV (other than for purposes of the 1940 Act) given the shared power/voting rights with its investing partner. Additionally, the Company’s investment strategy focuses primarily on directly originated middle market lending in senior secured first lien, second lien and equity investments, while the Logan JV focuses primarily on senior secured syndicated loans to larger issuers.

(2)

Gross additions may include increases in the cost basis of investments resulting from new portfolio investments, PIK interest or dividends, the accretion of discounts, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company into this category from a different category.

(3)

Gross reductions may include decreases in the cost basis of investments resulting from principal collections related to investment repayments or sales, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company out of this category into a different category.

Note 4. Investments

The information in the following tables is presented on an aggregate portfolio basis, without regard to whether they are non-controlled, non-affiliated; non-controlled, affiliated; or controlled affiliated, investments.

Investments at fair value consisted of the following (in thousands):

As of March 31, 2025As of December 31, 2024
Investment TypeCostFair ValueUnrealized Appreciation/ (Depreciation)CostFair ValueUnrealized Appreciation/ (Depreciation)
Senior Secured First Lien$414,229$400,297$(13,932)$395,736$379,627$(16,109)
Unitranche First Lien1,067,5561,048,878(18,678)1,055,5061,044,141(11,365)
Unitranche First Lien - Last Out24,77624,92214614,88814,741(147)
Senior Secured Second Lien27,97122,564(5,407)44,57138,537(6,034)
Unsecured Debt17,32518,20788216,69017,525835
Equity & Other49,71566,83317,11848,42164,86016,439
LLC/LP Equity Interests46,36339,040(7,323)48,09439,426(8,668)
Total investments$1,647,935$1,620,741$(27,194)$1,623,906$1,598,857$(25,049)

The industry composition of investments at fair value is as follows (in thousands):

Industry · Fair Value as of March 31, 2025 · Percentage of Fair Value · Fair Value as of December 31, 2024 · Percentage of Fair Value
Health Care Equipment & Services$451,94927.8%$436,18327.3%
Software & Services328,09220.2348,97921.8
Commercial & Professional Services245,28515.1231,59914.6
Consumer Services144,1298.9144,6719.0
Diversified Financials103,4526.495,9886.0
Insurance84,0045.283,6705.2
Pharmaceuticals, Biotechnology & Life Sciences67,4884.253,2303.3
Retailing56,7593.556,2193.5
Automobiles & Components35,1852.235,9882.3
Capital Goods30,4121.930,0051.9
Consumer Durables & Apparel17,0441.119,2441.2
Materials16,3441.016,4441.0
Food, Beverage & Tobacco13,2140.814,8010.9
Technology, Hardware & Equipment7,8880.57,9280.5
Household & Personal Products7,4660.57,4030.5
Transportation7,0470.48,2450.5
Energy3,2850.23,4760.2
Food & Staples Retailing1,6980.12,0050.1
Telecommunication Services00.000.0
Semiconductor and Semiconductor Equipment--2,7790.2
Total investments$1,620,741100.0%$1,598,857100.0%

The geographic composition of investments at fair value is as follows (in thousands):

Geographic Region · Fair Value as of March 31, 2025 · Percentage of Fair Value · Fair Value as of December 31, 2024 · Percentage of Fair Value
United States$1,446,21289.3%$1,452,24390.8%
United Kingdom82,2905.182,5565.2
Australia28,9541.828,6981.8
Switzerland21,6491.3--
Sweden16,3361.015,1130.9
Netherlands11,5760.710,0220.6
Jersey6,2810.46,0880.4
France5,4400.34,0150.3
Finland1,8990.1--
Belgium1040.01220.0
Total investments$1,620,741100.0%$1,598,857100.0%

Note 5. Fair Value of Financial Instruments

Investments

The following table presents fair value measurements of investments as of March 31, 2025 (in thousands):

Fair Value Hierarchy
Level 1 · Level 2 · Level 3 · Total
Senior Secured First Lien$—$—$400,297$400,297
Unitranche First Lien—26,4411,022,4371,048,878
Unitranche First Lien – Last Out——24,92224,922
Senior Secured Second Lien——22,56422,564
Unsecured Debt——18,20718,207
Equity & Other—94965,88466,833
Subtotal$—$27,390$1,554,311$1,581,701
Investments Measured at NAV (1)39,040
Total Investments$1,620,741
Foreign Currency Forward Contracts - Assets—4,242—4,242
Foreign Currency Forward Contracts - Liabilities—284—284

The following table presents fair value measurements of investments as of December 31, 2024 (in thousands):

Fair Value Hierarchy
Level 1 · Level 2 · Level 3 · Total
Senior Secured First Lien$—$—$379,628$379,628
Unitranche First Lien—30,2061,013,9341,044,140
Unitranche First Lien – Last Out——14,74114,741
Senior Secured Second Lien—14,18624,35138,537
Unsecured Debt——17,52517,525
Equity & Other—1,12563,73564,860
Subtotal$—$45,517$1,513,914$1,559,431
Investments Measured at NAV (1)39,426
Total Investments$1,598,857
Foreign Currency Forward Contracts - Assets—4,815—4,815
Foreign Currency Forward Contracts - Liabilities————

(1)

In accordance with ASC 820-10, certain investments that are measured using the net asset value per shares (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.

The following table provides a reconciliation of the beginning and ending balances for total investments that use Level 3 inputs for the three months ended March 31, 2025, based off of the fair value hierarchy as of March 31, 2025 (in thousands):

Senior SecuredFirst LienUnitrancheFirst LienUnitrancheFirst -Last OutSeniorSecuredSecond LienUnsecuredDebtEquity&OtherTotal
Balance as of January 1, 2025$379,628$1,013,934$14,741$24,351$17,525$63,735$1,513,914
Amortized discounts/premiums3681,34311(4)41—1,759
Paid in-kind interest432809216167593—2,217
Net realized gain (loss)(5,669)3—(693)—(454)(6,813)
Net change in unrealized appreciation (depreciation)2,176(7,124)29536446856(3,387)
Purchases32,59760,6589,659—21,747104,663
Sales/return of capital/principal repayments/paydowns(9,235)(50,693)—(1,621)——(61,549)
Transfers in—3,507————3,507
Transfers out——————-
Balance as of March 31, 2025$400,297$1,022,437$24,922$22,564$18,207$65,884$1,554,311
Net change in unrealized appreciation (depreciation) from investments still held as of March 31, 2025$(2,062)$(6,577)$295$62$46$402$(7,834)

During the three months ended March 31, 2025, the Company recordedno transfers from Level 3 to Level 2 and $3,507 in transfers from Level 2 to Level 3 due to a decrease in observable inputs in market data.

The following table provides a reconciliation of the beginning and ending balances for total investments that use Level 3 inputs for the three months ended March 31, 2024, based off of the fair value hierarchy as of March 31, 2024 (in thousands):

SeniorSecuredFirst LienUnitrancheFirst LienUnitrancheFirst -Last OutSeniorSecuredSecond LienUnsecuredDebtEquity&OtherTotal
Balance as of January 1, 2024$409,945$948,781$13,544$44,907$4,061$48,909$1,470,147
Amortized discounts/premiums6971,46813992—2,279
Paid in-kind interest442467192355109—1,565
Net realized gain (loss)(1,323)(12)(1,947)——1,678(1,604)
Net change in unrealized appreciation (depreciation)(606)2,1741,647(1,800)2632,3974,075
Purchases25,78945,257——3,39346374,902
Sales/return of capital/principal repayments/paydowns(29,375)(42,536)(906)(2,432)—(1,690)(76,939)
Transfers in—19,186—13,083——32,269
Transfers out———(3,330)——(3,330)
Balance as of March 31, 2024$405,569$974,785$12,543$50,882$7,828$51,757$1,503,364
Net change in unrealized appreciation (depreciation) from investments still held as of March 31, 2024$(606)$2,174$1,647$(1,800)$263$2,397$4,075

During the three months ended March 31, 2024, the Company recorded $3,330 in transfers from Level 3 to Level 2 due to an increase in observable inputs in market data and $32,269 in transfers from Level 2 to Level 3 due to a decrease in observable inputs in market data.

The following tables present the fair value of Level 3 investments and the ranges of significant unobservable inputs used to value the Company’s Level 3 investments as of March 31, 2025 and December 31, 2024. These ranges represent the significant unobservable inputs that were used in the valuation of each type of investment. These inputs are not representative of the inputs that could have been used in the valuation of any one investment. For example, the highest market yield presented in the table for senior secured first lien investments is appropriate for valuing a specific investment but may not be appropriate for valuing any other investment. Accordingly, the ranges of inputs presented below do not represent uncertainty in, or possible ranges of, fair value measurements of the Company’s Level 3 investments.

Security Type · Fair Value as of March 31, 2025(in thousands) · Valuation Technique · Unobservable Input · Range (Weighted Avg)
Senior Secured First Lien$324,245Discounted Cash FlowsDiscount Rate7.1%-17.7%(10.8%)
30,480Enterprise ValueComparable EBITDA Multiple2.8x-12.0x(7.1x)
21,317Transaction PrecedentTransaction PriceN/A
24,255Broker QuotedBroker QuoteN/A
$400,297
Unitranche First Lien$946,535Discounted Cash FlowsDiscount Rate8.8%-18.9%(10.7%)
19,769Enterprise ValueComparable EBITDA Multiple7.0x-11.0x(10.2x)
39,660Transactions PrecedentTransaction PriceN/A
16,473Broker QuotedBroker QuoteN/A
$1,022,437
Unitranche First Lien - Last Out$15,224Discounted Cash FlowsDiscount Rate10.9%-16.0%(12.6%)
9,698Transaction PrecedentTransaction PriceN/A
$24,922
Senior Secured Second Lien$19,853Discounted Cash FlowsDiscount Rate11.5%-13.4%(12.6%)
2,711Enterprise ValueComparable EBITDA Multiple3.4x-6.2x(4.9x)
$22,564
Unsecured Debt$16,322Discounted Cash FlowsDiscount Rate13.3%-15.3%(13.9%)
1,885Enterprise ValueComparable EBITDA Multiple12.0x
$18,207
Equity & Other$64,111Enterprise ValueComparable EBITDA Multiple2.8x-28.8x(15.2x)
1,773Transaction PrecedentTransaction PriceN/A
$65,884
Total$1,554,311
Security Type · Fair Value as of December 31, 2024(in thousands) · Valuation Technique · Unobservable Input · Range (Weighted Avg)
Senior Secured First Lien$324,549Discounted Cash FlowsDiscount Rate8.0%-18.3%(10.8%)
27,840Enterprise ValueComparable EBITDA Multiple3.1x-10.6x(8.1x)
2,779Discounted Cash FlowsRoyalty Payment Discount Rate22.4%
24,460Broker QuotedBroker QuoteN/A
$379,628
Unitranche First Lien$988,714Discounted Cash FlowsDiscount Rate8.9%-18.3%(10.7%)
12,556Enterprise ValueComparable Revenue Multiple10.9x
12,664Broker QuotedBroker QuoteN/A
$1,013,934
Unitranche First Lien - Last Out$14,741Discounted Cash FlowsDiscount Rate11.2%-16.0%(12.8%)
$14,741
Senior Secured Second Lien$15,802Discounted Cash FlowsDiscount Rate12.4%-14.1%(12.9%)
3,549Enterprise ValueComparable EBITDA Multiple1.4x-10.1x(5.1x)
5,000Broker QuotedBroker QuoteN/A
$24,351
Unsecured Debt$15,706Discounted Cash FlowsDiscount Rate13.3%-17.2%(14.2%)
1,819Enterprise ValueComparable EBITDA Multiple10.6x
$17,525
Equity & Other$63,735Enterprise ValueComparable EBITDA Multiple3.1x-27.4x(15.3x)
$63,735
Total$1,513,914

The significant unobservable inputs used in the fair value measurement of the Company’s debt and equity securities are primarily earnings before interest, taxes, depreciation and amortization (“EBITDA”), revenue, comparable multiples and market discount rates. The Company typically uses comparable EBITDA or revenue multiples on its equity securities to determine the fair value of investments. The Company uses discount rates for debt securities to determine if the effective yield on a debt security is commensurate with the market yields for that type of debt security.

The significant unobservable inputs used in the discounted cash flow approach is the discount rate used to discount the estimated future cash flows expected to be received from the underlying investment, which include both future principal and interest payments. Increases and decreases in the discount rate would result in a decrease and increase in the fair value, respectively. Included in the consideration and selection of discount rates is risk of default, rating of the investment, call provisions and comparable company investments.

The significant unobservable inputs used in the market multiple approach are the multiples of similar companies’ EBITDA, revenue and comparable market transactions. Increases and decreases in market EBITDA multiples and revenue would result in an increase or decrease in the fair value, respectively.

The recovery rate represents the extent to which proceeds can be recovered. An increase/decrease in the recovery rate would result in an increase/decrease, respectively, in the fair value. The transaction precedent represents an observable transaction or a pending event for the investment.

Note 6. Debt

Debt consisted of the following (in thousands):

March 31, 2025December 31, 2024
Aggregate Principal Amount CommittedDrawn AmountAmount Available (1)Carrying Value(2)(3)Aggregate Principal Amount CommittedDrawn AmountAmount Available (1)Carrying Value(2)(3)
SPV Asset Facility(9)$500,000$344,550$155,450$344,550$500,000$344,850$155,150$344,850
SMBC Corporate Revolving Facility310,000155,460154,540155,460310,000242,60167,399242,601
Series 2021A Unsecured Notes(4)135,000135,000—135,000135,000135,000—135,000
FCRX Unsecured Notes(5)111,600111,600—111,600111,600111,600—111,600
Series 2023A Unsecured Notes(6)50,00050,000—50,00050,00050,000—50,000
Series 2024A Unsecured Notes - 2028(7)35,00035,000—35,00035,000—35,000—
Series 2024A Unsecured Notes - 2030(8)80,00080,000—80,00080,000—80,000—
Total Debt$1,221,600$911,610$309,990$911,610$1,221,600$884,051$337,549$884,051

(1)

The amount available is subject to any limitations related to the respective debt facilities’ borrowing bases and foreign currency translation adjustments.

(2)

The amount presented excludes netting of deferred financing costs.

(3)

As of March 31, 2025 and December 31, 2024, the carrying amount of the Company’s outstanding debt approximated fair value unless otherwise noted.

(4)

As of March 31, 2025 and December 31, 2024, the fair value of the Series 2021A Unsecured Notes was approximately$131,888 and $133,280, respectively.

(5)

As of March 31, 2025 and December 31, 2024, the fair value of the FCRX Unsecured Notes was approximately $110,261 and $109,680.

(6)

As of March 31, 2025 and December 31, 2024, the fair value of the Series 2023A Unsecured Notes was approximately$50,876 and $52,027.

(7)

As of March 31, 2025, the fair value of the Series 2024A Unsecured Notes -2028 was approximately$35,088.

(8)

As of March 31, 2025, the fair value of the Series 2024A Unsecured Notes -2030 was approximately$80,387.

(9)

On April 10, 2025, the commitment amount was reduced from $500,000 to $400,000. See Note 13 for detail.

The combined weighted average interest rate of the aggregate borrowings outstanding for the three months ended March 31, 2025 and 2024 was 6.49% and 7.29% respectively. The combined weighted average debt of the aggregate borrowings outstanding for the three months ended March 31, 2025 and 2024 was$902,376 and $858,637 respectively.

The fair values of the Company’s debt are determined in accordance with ASC 820, which defines fair value in terms of the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions. The fair value of the Company's debt is calculated by discounting remaining payments using comparable market rates or market quotes for similar instruments at the measurement date. As of March 31, 2025 and December 31, 2024, all the debt except for FCRX Unsecured Notes would be deemed to be Level 3 of the fair value hierarchy. FCRX Unsecured Notes FCRX would be deemed to be Level 2 of the fair value hierarchy.

As of March 31, 2025 and December 31, 2024, the Company was in compliance with the terms and covenants of its debt arrangements.

SPV Asset Facility

On March 28, 2016, Crescent Capital BDC Funding, LLC (“CCAP SPV”), a wholly owned subsidiary of CCAP, entered into a loan and security agreement, as amended from time to time (the “SPV Asset Facility”), with the Company as the collateral manager, seller and equityholder, CCAP SPV as the borrower, the banks and other financial institutions from time to time party thereto as lenders, and Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, collateral agent, and lender. CCAP SPV is consolidated into the Company’s financial statements and no gain or loss is recognized from transfer of assets to and from CCAP SPV.

On May 31, 2024, CCAP SPV entered into the Seventh Amendment to Loan and Security Agreement. The amendment, among other things, (a) extended the last day of the reinvestment period to May 31, 2027, and the stated maturity date to May 31, 2029 and (b) reduced the spread from 2.75% to 2.45%.

The maximum commitment amount under the SPV Asset Facility is $500,000 and may be increased with the consent of Wells Fargo or reduced upon request of the Company. Proceeds of the advances under the SPV Asset Facility may be used to acquire portfolio investments, to make distributions to the Company in accordance with the SPV Asset Facility, and to pay related expenses.

The maturity date is the earlier of (a) the date the Borrower voluntarily reduces the commitments to zero, (b) May 31, 2029 and (c) the date upon which Wells Fargo declares the obligations due and payable after the occurrence of an Event of Default. Borrowings under the SPV Asset Facility bear interest at daily simple SOFR plus a 2.45% margin with no floor. The Company pays unused facility fees of 0.50% per annum on committed but undrawn amounts under the SPV Asset Facility. The unused facility fee rate may vary based on the utilization. The SPV Asset Facility includes customary covenants, including certain limitations on the incurrence of additional indebtedness and liens, as well as usual and customary events of default for revolving credit facilities of this nature. The facility size is subject to availability under the borrowing base, which is based on the amount of CCAP SPV’s assets from time to time, and satisfaction of certain conditions, including certain concentration limits.

Costs incurred in connection with obtaining the SPV Asset Facility were recorded as deferred financing costs and are being amortized over the life of the SPV Asset Facility on a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the SPV Asset Facility were $4,968 and $5,262, respectively, and were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

SMBC Corporate Revolving Facility

On October 27, 2021, the Company entered into a senior secured revolving credit agreement, as amended from time to time, with Sumitomo Mitsui Banking Corporation, as administrative agent, collateral agent and lender (the “SMBC Corporate Revolving Facility”). On December 3, 2024, the Company amended the SMBC Corporate Revolving Facility. The amendment, among other things, (i) decreased the size of the aggregate revolving commitment from $350,000 to $285,000, (ii) added an initial term commitment of $25,000 for an aggregate facility size of $310,000, (iii) increased the interest rate by 0.125% so that borrowings under the revolving commitment will bear interest at the applicable benchmark rate plus 2.000% or 2.125%, subject to certain provisions, (iii) extended the facility termination to December 3, 2029 and (iv) extended the facility revolving commitment period termination to December 1, 2028.

The maximum principal amount of the SMBC Corporate Revolving Facility is $310,000, comprised of $25,000 term loan and $285,000 revolving commitment, subject to availability under the borrowing base. Borrowings under the SMBC Corporate Revolving Facility bear interest atadjusted SOFR plus 2.000% or 2.125%, subject to certain provisions in the SMBC Corporate Revolving Facility agreement, with no benchmark rate floor. The Company pays unused facility fees of 0.375% per annum on committed but undrawn amounts under the SMBC Corporate Revolving Facility. Any amounts borrowed under the SMBC Corporate Revolving Facility, and all accrued and unpaid interest, will be due and payable, on December 3, 2029.

Costs incurred in connection with obtaining the SMBC Corporate Revolving Facility were recorded as deferred financing costs and are being amortized over the life of the SMBC Corporate Revolving Facility on an a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the SMBC Corporate Revolving Facility were $2,302 and $2,511, respectively, and were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

Series 2021A Unsecured Notes

On February 17, 2021, the Company completed a private offering of $135,000 aggregate principal amount of 4.00% senior unsecured notes due February 17, 2026 (the “Series 2021A Unsecured Notes”). The initial issuance of $50,000 of Series 2021A Unsecured Notes closed February 17, 2021. The issuance of the remaining $85,000 of Series 2021A Unsecured Notes closed on May 5, 2021.

The Series 2021A Unsecured Notes will mature on February 17, 2026 and may be redeemed in whole or in part, at the Company’s option, at any time or from time to time at par plus a “make-whole” premium, if applicable. Interest on the 2026 Unsecured Notes is due and payable semiannually in arrears on February 17 and August 17 of each year.

Costs incurred in connection with issuing the Series 2021A Unsecured Notes were recorded as deferred financing costs and are being amortized over the life of the Series 2021A Unsecured Notes on a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the Series 2021A Unsecured Notes were $252 and $323, respectively, and were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

FCRX Unsecured Notes

On March 9, 2023, in connection with the acquisition of First Eagle Alternative Capital BDC, Inc., the Company assumed $111,600 of unsecured notes (the "FCRX Unsecured Notes"). The FCRX Unsecured Notes mature on May 25, 2026 and may be redeemed in whole or in part at any time or from time to time at the Company’s option, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The FCRX Unsecured Notes bear interest at a rate of 5.00% peryear payable quarterly on March 30, June 30, September 30 and December 30 of each year. The FCRX Unsecured Notes trade on the New York Stock Exchange under the trading symbol “FCRX”.

Series 2023A Unsecured Notes

On May 9, 2023, the Company completed a private offering of $50,000 aggregate principal amount of 7.54% senior unsecured notes due July 28, 2026 ("Series 2023A Unsecured Notes").

The Series 2023A Unsecured Notes will mature on July 28, 2026 and may be redeemed in whole or in part, at the Company’s option, at any time or from time to time at par plus a “make-whole” premium, if applicable. Interest on the Series 2023A Unsecured Notes is due and payable semiannually in arrears on January 28 and July 28 of each year.

Costs incurred in connection with issuing the Series 2023A Unsecured Notes were recorded as deferred financing costs and are being amortized over the life of the 2026 Unsecured Notes - Series 2023A on a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the Series 2023A Unsecured Notes of $99 and $118 were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

Series 2024A Unsecured Notes - 2028 and 2030

On February 18, 2025, the Company issued $115,000 aggregate principal amount of two tranches of senior unsecured notes: (a) $35,000 6.77% notes due February 18, 2028 ("Series 2024A Unsecured Notes - 2028") and (b) $80,000 6.90% notes due February 18, 2030 ("Series 2024A Unsecured Notes – 2030") . Interest on both unsecured notes will be payable semiannually, on the 18th day of February and August in each year, commencing with August 18, 2025. Both tranches may be redeemed in whole or in part, at the Company’s option, at any time or from time to time at par plus a “make-whole” premium, if applicable.

Costs incurred in connection with issuing the Series 2024A Unsecured Notes - 2028 were recorded as deferred financing costs and are being amortized over the life of the Series 2024A Unsecured Notes - 2028 on a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the Series 2024A Unsecured Notes - 2028 of $312 and $0 were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

Costs incurred in connection with issuing the Series 2024A Unsecured Notes - 2030 were recorded as deferred financing costs and are being amortized over the life of the Series 2024A Unsecured Notes - 2030 on a straight line basis. As of March 31, 2025 and December 31, 2024, deferred financing costs related to the Series 2024A Unsecured Notes - 2028 of $724 and $0 were netted against debt outstanding on the Consolidated Statements of Assets and Liabilities.

Summary of Interest and Credit Facility Expenses

The borrowing expenses incurred by the Company's credit facilities and unsecured debt were as follows (in thousands):

For the three months ended March 31,
20252024
Borrowing interest expense$13,726$14,661
Unused facility fees289426
Amortization of financing costs621517
Total interest and credit facility expenses$14,636$15,604
Weighted average outstanding balance$902,376$858,637

Note 7. Derivatives

The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies.

In order to better define its contractual rights and to secure rights that will help mitigate its counterparty risk, the Company may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or a similar agreement with its derivative counterparties. An ISDA Master Agreement is a bilateral agreement between the Company and a counterparty that governs OTC derivatives, including foreign currency forward contracts, and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of a default (close-out netting) or similar event, including the bankruptcy or insolvency of the counterparty.

For financial reporting purposes, cash collateral that has been pledged to cover obligations of the Company and cash collateral received from the counterparty, if any, is included under restricted cash and cash equivalents on the Consolidated Statement of Assets and Liabilities. There has beenno cash collateral received or paid from the counterparty. The Company minimizes counterparty credit risk by only entering into agreements with counterparties that they believe to be of good standing and by monitoring the financial stability of those counterparties. All of the forward contracts qualify as Level 2 financial instruments.

During the three months ended March 31, 2025 and 2024 the Company’s average USD notional exposure, calculated daily on a weighted average basis on the duration of each forward contract, of foreign currency forward contracts was $64,788 and $63,179, respectively.

The following table sets forth the Company’s net exposure to foreign currency forward contracts that are subject to ISDA Master Agreements or similar agreements (in thousands):

Reporting DateCounterpartyGross Amountof Assets onthe ConsolidatedStatements ofAssets andLiabilitiesGross Amountof (Liabilities) onthe ConsolidatedStatements ofAssets andLiabilitiesNet Amount of Assetsor (Liabilities)Collateral(Received)Pledged (1)NetAmounts (2)
March 31, 2025Wells Fargo Bank, N.A.$4,242$(284)$3,958$—$3,958
December 31, 2024Wells Fargo Bank, N.A.$4,815$—$4,815$—$4,815

(1)

Amount excludes excess cash collateral paid.

(2)

Net amount represents the net amount due (to) from counterparty in the event of a default based on the contractual setoff rights under the agreement. Net amount excludes any over-collateralized amounts.

The effect of transactions in derivative instruments to the Consolidated Statements of Operations was as follows (in thousands):

For the three months ended March 31,
2025 · 2024
Net realized gain (loss) on foreign currency forward contracts$-$1,447
Net change in unrealized appreciation (depreciation) on foreign currency forward contracts(857)(356)
Total net realized and unrealized gains (losses) on foreign currency forward contracts$(857)$1,091

Note 8. Commitments, Contingencies and Indemnifications

The Company’s investment portfolio may contain investments that are in the form of lines of credit or unfunded commitments, which require the Company to provide funding when requested by portfolio companies in accordance with the terms of the underlying agreements. Unfunded commitments to provide funds to portfolio companies are not reflected on the Company’s Consolidated Statements of Assets and Liabilities. These commitments are subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that the Company holds. Since these commitments may expire without being drawn, the total commitment amount does not necessarily represent future cash requirements. As of March 31, 2025 and December 31, 2024, the Company had aggregated unfunded commitments totaling$212,378 and $212,459, respectively, including foreign denominated commitments converted to USD at the balance sheet date, under loan and financing agreements.

The Company has the following unfunded commitments to portfolio companies (in thousands):

As of March 31, 2025 · As of December 31, 2024
CompanyInvestment TypeCommitment Expiration Date (1)Unfunded Commitment (2)Commitment Expiration Date (1)Unfunded Commitment (2)
3SI Security Systems (7)Term Loan12/16/2026$4712/16/2026$—
ABACUS Holdings I LLC (7)Revolver6/22/20285506/22/2028550
ABACUS Holdings I LLC (7)Revolver6/24/20285086/24/2028689
ABACUS Holdings I LLC (7)Delayed Draw Term Loan7/24/20264,0006/22/20284,000
ACI Group Holdings, Inc. (6)Revolver8/2/20276498/2/2027664
Action Signature Acquisition, Inc. (5)Revolver6/17/20264206/17/2026212
Acu-Serve, LLC (7)Revolver10/18/202975010/18/2029750
Acu-Serve, LLC (7)Delayed Draw Term Loan10/18/20251,78010/18/20291,780
Advanced Diabetes Supply (7)Revolver12/30/202735012/30/2027350
Affinitiv, Inc. (7)Revolver7/26/20273687/26/2027425
Alcanza Clinical Research (5)Revolver12/15/202712512/15/2027—
Alera Group Inc.Delayed Draw Term Loan11/17/2025—9/30/2028167
Alpine SG, LLC (5)Revolver11/5/202710511/5/2027105
Ancora Bidco PTY LTD (5)Delayed Draw Term Loan11/6/20301,35411/6/20301,342
Annuity Health (7)Revolver2/8/20298002/8/2029800
APC Bidco LimitedDelayed Draw Term Loan11/10/20272,13010/11/20302,067
Apps Associates LLC (7)Revolver7/2/20276407/2/2027800
Arrow Management Acquisition, LLC (7)Revolver10/14/20271,20010/14/20271,200
Arrow Management Acquisition, LLC (7)Delayed Draw Term Loan11/28/20251,70910/14/20271,809
Automated Control Concepts, Inc. (5)Revolver10/22/202683310/22/2026833
Auveco Holdings (7)Revolver5/5/20284655/5/2028465
Avalign Technologies, Inc. (6)Revolver12/20/20281,16912/20/20281,169
Avidity Acquisition B.V. (7)Delayed Draw Term Loan3/4/2029575n/a—
AX VI INV2 Holding AB (Voff) (8)Revolver8/31/20294028/31/2029385
Balance Partners (7)Revolver4/3/20305504/3/2030550
Balance Partners (7)Delayed Draw Term Loan4/3/20301,5064/3/20303,250
Bandon Fitness (Texas) Inc. (7)Revolver7/27/20284017/27/2028401
Banker's Toolbox, Inc. (6)Revolver7/27/20272,4067/27/20272,406
Bayside Opco, LLC (7)Revolver5/31/20266345/31/2026634
Belay Inc. (7)Revolver11/15/20256506/25/2026650
Benesys Inc.Revolver10/3/2025—10/3/2025(2)
Benesys Inc.Revolver10/3/2025—10/3/202524
Blue Mantis (6)Revolver8/5/20306308/19/2030630
BVI Medical Inc. (6)Delayed Draw Term Loan9/7/2027442n/a—
BVI Medical Inc. (6)Revolver3/7/2032821n/a—
C-4 Analytics (7)Revolver5/14/20301,2955/14/20301,295
C-4 Analytics (7)Delayed Draw Term Loan5/14/20264,6505/14/20304,650
Career Certified, LLC (7)Delayed Draw Term Loan2/19/2031450n/a—
Career Certified, LLC (7)Revolver2/19/2031350n/a—
CC Amulet Management, LLC (7)Revolver8/31/2027978/31/202797
Centria Subsidiary Holdings, LLC (7)Revolver12/9/20251,7376/9/20271,974
Claritas, LLC (7)Revolver3/31/20261,9503/31/20261,950
Concord III, LLC (7)Term Loan12/20/202813812/20/2028275
ConvenientMD (5)Revolver6/15/20276886/15/2029688
DataVailRevolver1/4/2029—1/4/2029(4)
DataVailRevolver1/4/2029—1/4/2029192
DataVail (7)Delayed Draw Term Loan1/4/20291,8981/4/20292,128
Duraserv LLCDelayed Draw Term Loan6/10/2026—6/10/2031899
Duraserv LLC (6)Delayed Draw Term Loan3/3/20271,715n/a—
Duraserv LLC (6)Revolver6/10/20308936/10/2030893
Eagle Midco B.V. (Avania) (10)Delayed Draw Term Loan7/5/20292,6647/5/20292,552
Effective School Solutions LLC (7)Revolver11/30/2027290n/a—
Effective School Solutions LLC (7)Revolver11/30/202740611/30/2027348
Efor HoldingDelayed Draw Term Loan10/4/2026—10/4/2030120
EMS Buyer, Inc. (7)Revolver11/23/202714711/23/2027147
Envocore Holding, LLC (5)Revolver12/31/202569412/31/20251,806
Eshipping (7)Revolver11/5/20271,15011/5/20271,150
Essential Services Holding Corporation (6)Revolver6/17/20317816/17/2031929
Essential Services Holding Corporation (6)Delayed Draw Term Loan6/17/20301,4876/17/20301,487
Evergreen IX Borrower 2023, LLC (6)Revolver9/29/20291,5009/29/20291,500
Everlast Parent Inc. (7)Revolver10/30/202678310/30/2028783
Evolution BuyerCo, Inc. (7)Revolver4/30/20307294/30/2027729
Flow Service Partners Intermediate Holdco LLC (7)Revolver11/19/203061311/19/2030800
Flow Service Partners Intermediate Holdco LLC (7)Delayed Draw Term Loan11/19/20301,35011/19/20301,350
Formulations Parent Corporation (6)Revolver11/15/20291,65111/15/20291,651
FS Whitewater Borrower, LLC (3)Delayed Draw Term Loan3/31/20271,744n/a—
FS Whitewater Borrower, LLC (6)Revolver12/21/202769012/21/2027690
Galway Borrower, LLC (6)Revolver9/30/20272869/30/2028417
Galway Borrower, LLC (6)Revolver9/30/20285659/30/2028565
Galway Borrower, LLC (6)Delayed Draw Term Loan2/7/20265959/30/2028599
GB Eagle Buyer, Inc. (7)Revolver11/29/203044911/29/2030513
GB Eagle Buyer, Inc. (7)Delayed Draw Term Loan11/29/20301,28211/29/20301,282
Gener8, LLC (5)Revolver8/14/20252998/14/2025299
GH Parent Holdings Inc. (7)Delayed Draw Term Loan5/4/20271,1725/4/20271,172
GH Parent Holdings Inc. (7)Revolver5/4/20271,8195/4/20271,819
GrapeTree Medical Staffing, LLC (7)Revolver4/30/20266004/30/2026600
Great Lakes Dental Partners, LLC (7)Revolver6/23/20261006/23/2026100
Guardian Access Solutions (7)Revolver8/1/20294138/24/2029413
Guardian Access Solutions (7)Delayed Draw Term Loan8/1/20299748/24/2029974
Halo Buyer, Inc. (7)Revolver8/7/2029496n/a—
Hamsard 3778 LimitedDelayed Draw Term Loan10/28/20311,41710/28/20311,375
Hercules Borrower LLC (7)Revolver12/15/20262,22212/15/20262,222
HGH Purchaser, Inc. (6)Revolver11/3/20251,00611/1/20261,547
Homecare Partners Management, LLC (7)Revolver5/25/20273085/25/2027249
Homecare Partners Management, LLC (7)Delayed Draw Term Loan6/18/20301,8366/18/20301,836
Hospice Care Buyer, Inc. (7)Revolver12/9/202652212/9/2026660
HS Spa Holdings Inc. (Hand & Stone) (6)Delayed Draw Term Loan6/2/20295016/2/2029501
HS Spa Holdings Inc. (Hand & Stone) (6)Revolver6/2/20281,0206/2/20281,209
Hsid Acquisition, LLC (7)Revolver1/31/20267501/31/2026750
iLending LLC (5)Revolver6/21/20267186/21/2026718
Imagenet, LLC (7)Revolver12/31/203065012/31/2030650
Infobase (7)Revolver6/14/20284306/14/2028643
Integrity Marketing Acquisition, LLC (6)Revolver8/28/20281,4098/28/20281,409
Iris Buyer, LLC (7)Delayed Draw Term Loan8/4/20262,156n/a—
Iris Buyer, LLC (7)Delayed Draw Term Loan3/29/202551510/2/2030515
Iris Buyer, LLC (7)Revolver10/2/20291,05910/2/20291,514
IVX Health Merger Sub, Inc. (7)Revolver6/7/20303,5196/7/20303,519
Jordan Bidco, Ltd. (10)Delayed Draw Term Loan2/29/20273,4198/31/20283,317
JTM Foods LLC (7)Revolver5/14/20273205/14/202753
King Mid LLCDelayed Draw Term Loan6/7/2026—12/15/20271,592
King Mid LLC (7)Delayed Draw Term Loan4/23/20311,106n/a—
King Mid LLC (7)Revolver12/15/202730012/15/2027300
Lash Opco LLC (7)Revolver9/18/202549/18/20254
Learn-It Systems, LLC (7)Revolver3/18/20257209/18/2026900
Lexipol (Ranger Buyer, Inc.) (6)Revolver11/18/20271,10511/18/20271,105
Lighthouse Lab Services (7)Revolver10/25/202715310/25/2027153
Lightspeed Buyer, Inc. (7)Revolver2/3/20271,1002/3/20271,100
Lightspeed Buyer, Inc. (7)Delayed Draw Term Loan2/3/20274642/3/20271,250
Lion Cashmere Bidco Limited (5)Delayed Draw Term Loan3/23/20282,9813/23/20282,856
List Partners, Inc. (7)Revolver6/30/20251356/30/2025135
Mann Lake Ltd.Revolver——1/31/202556
Mario Purchaser, LLC (6)Revolver4/26/20286614/26/2028731
Mario Purchaser, LLC (7)Delayed Draw Term Loan4/26/20294,3054/26/20294,305
Marlin DTC-LS Midco 2, LLC (7)Revolver7/1/20251437/1/2025143
MB2 Dental (6)Delayed Draw Term Loan2/13/20273972/13/2031397
MB2 Dental (6)Revolver2/13/20314272/13/2031427
MB2 Dental (6)Delayed Draw Term Loan2/13/20261,4422/13/20311,698
Medical Review Institute of America (7)Revolver7/1/20306887/1/2030800
Medicus IT (6)Revolver7/9/20309907/9/20301,100
Medicus IT (6)Delayed Draw Term Loan7/9/20262,8007/9/20302,800
MeriCal, LLC (5)Revolver11/16/202531511/16/2025485
MHS Acquisition Holdings, LLC (7)Delayed Draw Term Loan7/21/202717/21/20271
MHS Acquisition Holdings, LLC (7)Revolver7/21/2027907/21/2027120
Minuteman Security Technologies, Inc. (7)Delayed Draw Term Loan2/2/20259282/2/2029928
Minuteman Security Technologies, Inc. (7)Revolver2/1/20291,0002/2/20291,000
Miracle Mile Holdings, LLC (7)Delayed Draw Term Loan2/28/20275,200n/a—
Miracle Mile Holdings, LLC (7)Revolver11/1/2028100n/a—
MRI Software LLC (6)Delayed Draw Term Loan2/10/20277272/10/2027949
MRI Software LLC (7)Revolver2/10/20261,4602/10/20261,460
MWD Management LLC (United Derm) (7)Revolver6/15/20277206/15/2027720
Net Health Acquisition Corp. (6)Revolver7/5/20311,5347/5/20311,432
Newcleus, LLC (5)Revolver8/2/20264358/2/2026435
Newcleus, LLC (5)Delayed Draw Term Loan8/2/20264588/2/2026458
NRG Controls (7)Revolver10/28/203045010/28/2030450
NRG Controls (7)Delayed Draw Term Loan10/28/203080010/28/2030800
Nurture LandscapesDelayed Draw Term Loan6/3/2028—6/3/20286,243
Odessa Technologies, Inc. (6)Revolver10/19/20272,50010/19/20272,500
Oliver Packaging LLC (7)Revolver7/6/20283517/6/2028351
Omega Systems Intermediate Holdings, Inc. (6)Delayed Draw Term Loan1/15/20271,200n/a—
Omega Systems Intermediate Holdings, Inc. (6)Revolver1/15/2031400n/a—
Omni Ophthalmic Management Consultants, LLC (7)Revolver9/30/2025323n/a—
Online Labels Group, LLC (7)Delayed Draw Term Loan12/19/202526312/19/2029525
Online Labels Group, LLC (7)Delayed Draw Term Loan12/19/202552512/19/2029525
Online Labels Group, LLC (7)Revolver12/19/202965012/19/2029650
Painters Supply & Equipment Company (7)Revolver8/10/20273338/10/2027183
Painters Supply & Equipment Company (7)Delayed Draw Term Loan4/29/20305784/29/2030578
Patriot Acquisition Topco S.A.R.L (7)Delayed Draw Term Loan10/13/20258971/29/2028890
Patriot Acquisition Topco S.A.R.L (7)Revolver1/29/20268221/29/20261,770
Patriot Growth Insurance Services, LLC (6)Delayed Draw Term Loan11/16/202529510/14/2028295
Patriot Growth Insurance Services, LLC (6)Revolver10/14/202833010/14/2028330
PCS Retirement (7)Revolver3/1/20305783/1/2030578
PCS Retirement (7)Delayed Draw Term Loan2/27/20268603/1/2030860
Pitch MidCo B.V.Delayed Draw Term Loan4/26/20281,5484/26/20311,484
Plasma Buyer LLC (PathGroup)Delayed Draw Term Loan5/12/2029—5/12/202954
Plasma Buyer LLC (PathGroup) (6)Revolver5/12/20291415/12/2029357
PPV Intermediate Holdings LLC (Vetcor) (6)Revolver8/31/20292288/31/2029228
Premier Dental Care Management, LLC (6)Revolver8/5/20272,1258/5/20272,125
Premier Dental Care Management, LLC (6)Delayed Draw Term Loan8/5/20282,0938/5/20282,562
PromptCare Intermediate, LP (7)Delayed Draw Term Loan10/20/20252,1114/19/20302,111
Pye-Barker Fire & Safety, LLC (6)Revolver5/24/20302,2895/24/20302,289
Quorum Health Resources (5)Revolver5/26/20276745/26/2027674
Receivable Solutions, Inc. (7)Revolver10/1/202515010/1/2025180
REP Behavioral Health, LLC (7)Revolver12/31/20301,26612/31/20301,329
REP Behavioral Health, LLC (7)Delayed Draw Term Loan12/31/20302,50012/31/20302,500
Right Networks, LLCRevolver——5/21/2026233
Right Networks, LLC (7)Revolver5/29/2029570n/a—
RN Enterprises, LLC (6)Revolver10/17/20311,06310/17/20311,106
RN Enterprises, LLC (6)Delayed Draw Term Loan10/17/20312,18310/17/20312,183
RWA Wealth Partners, LLC. (6)Revolver11/15/20301,40011/15/20301,400
RWA Wealth Partners, LLC. (6)Delayed Draw Term Loan11/15/20304,64111/15/20304,641
Safco Dental Supply, LLC (7)Revolver6/14/20252586/14/2025258
Saturn Borrower Inc (7)Revolver9/30/20261,8169/30/2026—
SC MidCo Oy (7)Delayed Draw Term Loan3/19/2032162n/a—
Seniorlink Incorporated (7)Revolver12/31/202745812/31/2027458
Seniorlink Incorporated (7)Revolver12/31/20271,03812/31/20271,038
Slickdeals Holdings, LLC (7)Revolver6/30/20257276/30/2025727
Smartronix, LLCRevolver——11/23/20283,290
Smile Doctors LLC (6)Revolver12/23/20271,26212/23/20271,262
Soltis (7)Revolver8/5/20305008/5/2030500
Soltis (7)Delayed Draw Term Loan8/5/20262,6008/5/20302,600
Solvias AG (6)Revolver2/27/20322,956n/a—
SQAD Holdco, Inc. (7)Revolver4/25/20281,0504/25/20281,050
Stepping Stones Healthcare Services, LLC (6)Revolver12/30/20261,88712/30/20261,887
Stepping Stones Healthcare Services, LLC (6)Delayed Draw Term Loan4/25/20262,73612/30/20283,396
Strata Information Group, Inc. (6)Revolver12/31/203070012/31/2030350
Strata Information Group, Inc. (6)Delayed Draw Term Loan12/31/203088212/31/20301,200
Summit 7 Systems, LLC (7)Revolver5/23/20285285/23/2028264
Sun Acquirer Corp. (6)Revolver9/8/20271,8129/5/20271,812
Sydney US Buyer Corp. (3B Scientific) (10)Delayed Draw Term Loan12/14/20263,9607/8/20293,960
Sydney US Buyer Corp. (3B Scientific) (5)Delayed Draw Term Loan7/8/2029257/8/202925
Teal Acquisition Co., IncRevolver9/22/2026—9/22/2026182
Team Select (CSC TS Merger SUB, LLC) (7)Revolver5/4/20296505/4/2029650
Team Select (CSC TS Merger SUB, LLC) (7)Delayed Draw Term Loan6/17/20308006/17/2030800
Team Select (CSC TS Merger SUB, LLC) (7)Delayed Draw Term Loan5/4/20298405/4/2029840
The Hilb Group, LLC (6)Revolver12/2/20251,59410/31/20311,547
The Hilb Group, LLC (6)Delayed Draw Term Loan10/31/20263,28210/31/20313,341
TMA Buyer, LLC (5)Revolver9/30/20273859/30/2027385
Transportation Insight, LLC (5)Revolver6/18/2027516/18/2027412
TriStrux, LLC (7)Revolver12/15/20269712/15/202697
UHY Advisors , Inc. (6)Revolver11/21/203193311/21/20311,200
UHY Advisors , Inc. (6)Delayed Draw Term Loan11/21/20314,57511/21/20314,575
Unifeye Vision PartnersRevolver9/13/2025—9/15/2025453
USA Hometown Experts, Inc. (7)Revolver11/8/202972011/8/2029720
USA Hometown Experts, Inc. (7)Delayed Draw Term Loan11/18/20252,45011/8/20292,450
Vantage Insurance Partners, Inc. (7)Revolver12/22/202869812/22/2028698
Vantage Insurance Partners, Inc. (7)Delayed Draw Term Loan3/20/20264,60012/22/20284,600
Vital Care Buyer, LLC (6)Revolver7/30/20312837/30/2031283
WCT Group Holdings, LLC (6)Revolver12/12/202945712/12/2029457
Winxnet Holdings LLC (7)Revolver12/29/202524412/29/2025244
Total$212,378$212,459

(1)

Commitments are generally subject to borrowers meeting certain criteria such as compliance with covenants and certain operational metrics. These amounts may remain outstanding until the commitment period of an applicable loan expires, which may be shorter than its maturity.

(2)

Unfunded commitments denominated in currencies other than USD have been converted to USD using the applicable foreign currency exchange rate as of March 31, 2025 and December 31, 2024.

(3)

Investment pays 0.25% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(4)

Investment pays 0.38% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(5)

Investment pays 0.50% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(6)

Investment pays 0.75% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(7)

Investment pays 1.00% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(8)

Investment pays 1.20% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(9)

Investment pays 1.50% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(10)

Investment pays 1.80% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(11)

Investment pays 1.88% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(12)

Investment pays 2.25% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(13)

Investment pays 2.88% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

(14)

Investment pays 5.00% unfunded commitment fee on delayed draw term loan and/or revolving credit facilities.

Other Commitments and Contingencies

In the normal course of business, the Company enters into contracts which provide a variety of representations and warranties, and that provide general indemnifications. Such contracts include those with certain service providers, brokers and trading counterparties. Any exposure to the Company under these arrangements is unknown as it would involve future claims that may be made against the Company; however, based on the Company’s experience, the risk of loss is remote and no such claims are expected to occur. As such, the Company has not accrued any liability in connection with such indemnifications.

Note 9. Net Assets

The following table summarizes the Company’s recent distributions declared:

Date DeclaredRecord DatePayment DateDividend TypeAmount Per Share
February 12, 2025August 29, 2025September 15, 2025Special$0.05
February 12, 2025May 30, 2025June 14, 2025Special$0.05
February 12, 2025March 31, 2025April 15, 2025Regular$0.42
February 12, 2025February 28, 2025March 14, 2025Special$0.05
November 12, 2024December 31, 2024January 15, 2025Regular$0.42
November 12, 2024November 29, 2024December 16, 2024Supplemental$0.07
August 7, 2024September 30, 2024October 15, 2024Regular$0.42
August 7, 2024August 31, 2024September 16, 2024Supplemental$0.09
May 2, 2024June 28, 2024July 15, 2024Regular$0.42
May 2, 2024May 31, 2024June 17, 2024Supplemental$0.11
February 15, 2024March 29, 2024April 15, 2024Regular$0.41
February 15, 2024February 29, 2024March 15, 2024Supplemental$0.10
November 2, 2023December 29, 2023January 16, 2024Regular$0.41

At March 31, 2025 and December 31, 2024, Crescent, Sun Life and other related parties owned 8.76% and 8.75%, respectively, of the outstanding common shares of the Company.

Note 10. Earnings Per Share

In accordance with the provisions of ASC 260 –Earnings per Share (“ASC 260”), basic earnings per share is computed by dividing earnings available to common stockholders by the weighted average number of shares outstanding during the period. Other potentially dilutive common shares, and the related impact to earnings, are considered when calculating earnings per share on a diluted basis. As of March 31, 2025 and December 31, 2024, there are no dilutive shares.

The following table sets forth the computation of the weighted average basic and diluted net increase in net assets per share from operations for the following periods (in thousands):

For the three months ended March 31,
20252024
Net increase (decrease) in net assets resulting from operations$3,904$28,005
Weighted average common shares outstanding37,061,54737,061,547
Net increase (decrease) in net assets resulting from operations per common share-basic and diluted$0.11$0.76

Note 11. Income Taxes

The Company’s aggregate investment unrealized appreciation and depreciation for federal income tax purposes was as follows (in thousands):

As ofMarch 31, 2025 · As ofDecember 31, 2024
Tax Cost$1,683,924$1,663,941
Gross Unrealized Appreciation$41,927$40,639
Gross Unrealized Depreciation(107,688)(100,760)
Net Unrealized Investment Appreciation (Depreciation)$(65,761)$(60,121)

The Company recognized the following income taxes related to Taxable Subsidiaries and excise taxes related to the Company’s status as a RIC:

For the three months ended March 31,
2025 · 2024
Income tax (benefit) provision$6$-
Excise tax (benefit) provision495366
Provision (benefit) for income and excise taxes$501$366

As of March 31, 2025 and December 31, 2024,$196 and $1,408, respectively, of accrued income and excise taxes remained payable.

The Company recognized the following benefits (provisions) for taxes on realized and unrealized appreciation and depreciation on investments:

For the three months ended March 31,
2025 · 2024
Benefit (provision) for taxes on unrealized appreciation (depreciation) on investments-339
Benefit (provision) for taxes on realized and unrealized appreciation (depreciation) on investments$-$339

As of March 31, 2025 and December 31, 2024,$282 and $746, respectively, was included in deferred tax assets on the Consolidated Statements of Assets and Liabilities relating to net operating loss carryforwards and unrealized losses on investments and other temporary book to tax differences that are expected to be used in future periods. As of March 31, 2025 and December 31, 2024,$282 and $746, respectively, was included in deferred tax liabilities on the Consolidated Statements of Assets and Liabilities primarily relating to deferred taxes on unrealized gains on investments held in the Company’s corporate subsidiaries and other temporary book to tax differences of the corporate subsidiaries.

Note 12. Financial Highlights

Below is the schedule of the Company’s financial highlights (in thousands, except share and per share data):

For the three months ended March 31,
20252024
Per Share Data:(1)
Net asset value, beginning of period$19.98$20.04
Net investment income after tax0.450.63
Net realized and unrealized gains (losses) on investments and forward contracts, net of taxes(0.34)0.13
Net increase (decrease) in net assets resulting from operations0.110.76
Distributions declared from net investment income(2)(0.47)(0.51)
Effects of rounding—(0.01)
Total increase (decrease) in net assets(0.36)0.24
Net asset value, end of period$19.62$20.28
Shares outstanding, end of period37,061,54737,061,547
Market value, end of period$17.12$17.26
Weighted average shares outstanding37,061,54737,061,547
Total return based on market value (3)(8.49%)2.28%
Total return based on net asset value (4)0.55%3.74%
Ratio/Supplemental Data:
Net assets, end of period$727,122$751,698
Ratio of total net expenses to average net assets(5)14.10%14.56%
Ratio of net expenses (without incentive fees and interest and other debt expenses) to average net assets4.08%3.52%
Ratio of net investment income before taxes to average net assets (6)9.46%12.75%
Ratio of interest and credit facility expenses to average net assets (6)8.09%8.40%
Ratio of net incentive fees to average net assets (6)1.93%2.64%
Portfolio turnover (7)4.82%4.70%
Asset coverage ratio179%189%

(1)

Based on actual number of shares outstanding at the end of the corresponding period or the weighted average shares outstanding for the period, unless otherwise noted, as appropriate.

(2)

The per share data for distributions per share reflects the actual amount of distributions declared per share for the applicable periods.

(3)

Total return based on market value is calculated as the change in market value per share during the period, taking into account dividends, if any, reinvested in accordance with the Company’s dividend reinvestment plan.

(4)

Total return based on net asset value is calculated as the change in net asset value per share during the period plus declared dividends per share during the period, divided by the beginning net asset value per share, and not annualized.

(5)

The ratio of total expenses to average net assets in the table above reflects the Adviser’s voluntary waivers of its right to receive a portion of the management fees and income incentive fees with respect to the Company’s ownership in GACP II LP, WhiteHawk III Onshore Fund LP and Freeport Financial SBIC Fund LP and a voluntary waiver of income incentive fees to the extent net investment income, excluding the effect of the GAAP incentive fee, falls short of the regular declared dividend on a full dollar basis. Excluding the effects of the voluntary waivers, the ratio of total expenses to average net assets would have been 14.21% and 14.60% for the three months ended March 31, 2025 and 2024, respectively.

(6) Annualized.

(7) Not annualized.

Note 13. Subsequent Events

The Company’s management evaluated subsequent events through the date of issuance of the consolidated financial statements included herein. Other than the items below, there have been no subsequent events that occurred during such period that would require disclosure in this Form 10-Q or would be required to be recognized in the consolidated financial statements as of March 31, 2025 and for the three months ended March 31, 2025.

On April 10, 2025, CCAP SPV entered into the Eighth Amendment to Loan and Security Agreement. The amendment, among other things, (a) reduced the spread from 2.45% to 1.95%, and (b) reduced the facility size from $500,000 to $400,000.

On May 8, 2025, the Company's Board of Directors declared a regular second quarter cash dividend of $0.42 per share, which will be paid on July 15, 2025 to stockholders of record as of June 30, 2025.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.